Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

BMY Income Statement

Revenue, expenses, and profitability analysis

BMY Quarterly Income Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
33.330B8.068B8.405B8.787B8.070B7.340B7.424B6.617B6.801B
48.482B11.489B12.502B12.222B12.269B11.201B12.342B11.892B12.201B
Cost of Goods Sold
15.152B3.421B4.097B3.435B4.199B3.861B4.918B5.275B5.400B
70.2%70.2%67.2%71.9%65.8%65.5%60.2%55.6%55.7%
Total Operating Expenses
20.884B4.797B6.986B5.148B3.953B3.819B4.893B4.329B4.217B
10.025B2.649B2.586B2.528B2.262B2.236B2.788B2.353B2.295B
7.278B1.617B2.181B1.789B1.691B1.583B1.852B1.976B1.922B
12.446B3.271B1.419B3.639B4.117B3.521B2.531B2.288B2.584B
28.5%28.5%11.4%29.8%33.6%31.4%20.5%19.2%21.2%
9.597B3.240B1.470B3.114B1.773B2.971B175.000M1.676B1.286B
Interest Income
300.000M161.000M139.000M
1.016B51.000M480.000M485.000M494.000M496.000M505.000M521.000M
Other Income/Expense
-2.849B-31.000M51.000M-525.000M-2.344B-550.000M-2.356B-612.000M-1.298B
7.275B2.678B1.086B2.201B1.310B2.456B72.000M1.211B1.680B
2.324B561.000M384.000M919.000M460.000M509.000M99.000M461.000M-398.000M
23.3%23.3%8.7%18.0%10.7%21.9%0.6%10.2%13.8%
13.776B3.708B2.194B4.587B3.287B4.477B2.551B4.773B4.403B
EBITDA Margin
32.3%32.3%17.5%37.5%26.8%40.0%20.7%40.1%36.1%
3.285B437.000M826.000M993.000M1.029B1.012B1.880B2.592B2.596B
EPS Basic
3.561.310.531.080.641.210.040.600.83
3.561.310.531.080.641.200.040.600.83
Shares Outstanding
2.044B2.044B2.041B2.038B2.035B2.031B2.029B2.028B2.027B
Diluted Shares Outstanding
2.044B2.044B2.041B2.038B2.038B2.037B2.037B2.031B2.029B

BMY Annual Income Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
32.602B27.432B25.357B26.490B26.761B21.700B17.250B16.075B
48.194B48.300B45.006B46.159B46.385B42.518B26.145B22.561B
Cost of Goods Sold
15.592B20.868B19.649B19.669B19.624B20.818B8.895B6.486B
67.6%56.8%56.3%57.4%57.7%51.0%66.0%71.3%
Total Operating Expenses
19.906B17.774B16.885B17.219B17.221B17.208B10.811B9.681B
9.612B9.782B9.207B9.411B9.533B9.557B5.949B5.131B
7.244B7.865B7.678B7.808B7.688B7.651B4.862B4.550B
12.696B9.658B8.472B9.271B9.540B4.492B6.439B6.394B
26.3%20.0%18.8%20.1%20.6%10.6%24.6%28.3%
9.328B-8.379B8.440B7.713B8.098B-6.871B4.975B5.968B
Interest Income
300.000M
1.510B1.947B1.166B1.232B1.334B1.420B656.000M183.000M
Other Income/Expense
-3.368B-18.037B-32.000M-1.558B-1.442B-11.363B-1.464B-426.000M
7.053B-8.948B8.025B6.327B6.994B-8.995B3.439B4.920B
2.272B554.000M400.000M1.368B1.084B2.124B1.515B1.021B
14.6%-18.5%17.8%13.7%15.1%-21.2%13.2%21.8%
14.545B3.168B19.366B19.221B20.118B4.929B7.377B6.788B
EBITDA Margin
30.2%6.6%43.0%41.6%43.4%11.6%28.2%30.1%
3.860B9.600B9.760B10.276B10.686B10.380B1.746B637.000M
EPS Basic
3.46-4.413.882.973.15-3.982.023.03
3.45-4.413.862.953.12-3.982.013.03
Shares Outstanding
2.041B2.027B2.069B2.130B2.221B2.258B1.705B1.633B
Diluted Shares Outstanding
2.041B2.027B2.078B2.146B2.245B2.258B1.712B1.637B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner